Ginsenoside Rg1 alleviates chronic inflammation-induced neuronal ferroptosis and cognitive impairments via regulation of AIM2 - Nrf2 signaling pathway

J Ethnopharmacol. 2024 Aug 10:330:118205. doi: 10.1016/j.jep.2024.118205. Epub 2024 Apr 17.

Abstract

Ethnopharmacological relevance: Ginseng is a valuable herb in traditional Chinese medicine. Modern research has shown that it has various benefits, including tonifying vital energy, nourishing and strengthening the body, calming the mind, improving cognitive function, regulating fluids, and returning blood pressure, etc. Rg1 is a primary active component of ginseng. It protects hippocampal neurons, improves synaptic plasticity, enhances cognitive function, and boosts immunity. Furthermore, it exhibits anti-aging and anti-fatigue properties and holds great potential for preventing and managing neurodegenerative diseases (NDDs).

Aim of the study: The objective of this study was to examine the role of Rg1 in treating chronic inflammatory NDDs and its molecular mechanisms.

Materials and methods: In vivo, we investigated the protective effects of Rg1 against chronic neuroinflammation and cognitive deficits in mice induced by 200 μg/kg lipopolysaccharide (LPS) for 21 days using behavioral tests, pathological sections, Western blot, qPCR and immunostaining. In vitro experiments involved the stimulation of HT22 cells with 10 μg/ml of LPS, verification of the therapeutic effect of Rg1, and elucidation of its potential mechanism of action using H2DCFDA staining, BODIPY™ 581/591 C11, JC-1 staining, Western blot, and immunostaining.

Results: Firstly, it was found that Rg1 significantly improved chronic LPS-induced behavioral and cognitive dysfunction in mice. Further studies showed that Rg1 significantly attenuated LPS-induced neuronal damage by reducing levels of IL-6, IL-1β and ROS, and inhibiting AIM2 inflammasome. Furthermore, chronic LPS exposure induced the onset of neuronal ferroptosis by increasing the lipid peroxidation product MDA and regulating the ferroptosis-associated proteins Gpx4, xCT, FSP1, DMT1 and TfR, which were reversed by Rg1 treatment. Additionally, Rg1 was found to activate Nrf2 and its downstream antioxidant enzymes, such as HO1 and NQO1, both in vivo and in vitro. In vitro studies also showed that the Nrf2 inhibitor ML385 could inhibit the anti-inflammatory, antioxidant, and anti-ferroptosis effects of Rg1.

Conclusions: This study demonstrated that Rg1 administration ameliorated chronic LPS-induced cognitive deficits and neuronal ferroptosis in mice by inhibiting neuroinflammation and oxidative stress. The underlying mechanisms may be related to the inhibition of AIM2 inflammasome and activation of Nrf2 signaling. These findings provide valuable insights into the treatment of chronic neuroinflammation and associated NDDs.

Keywords: AIM2 inflammasome; Ferroptosis; Ginsenoside Rg1; Nrf2 signaling; Oxidative stress.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Cell Line
  • Cognitive Dysfunction* / drug therapy
  • Cognitive Dysfunction* / metabolism
  • DNA-Binding Proteins
  • Ferroptosis* / drug effects
  • Ginsenosides* / pharmacology
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Lipopolysaccharides / toxicity
  • Male
  • Mice
  • Mice, Inbred C57BL
  • NF-E2-Related Factor 2* / metabolism
  • Neuroinflammatory Diseases / drug therapy
  • Neuroinflammatory Diseases / metabolism
  • Neurons* / drug effects
  • Neurons* / metabolism
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Signal Transduction* / drug effects

Substances

  • Ginsenosides
  • NF-E2-Related Factor 2
  • ginsenoside Rg1
  • Nfe2l2 protein, mouse
  • Aim2 protein, mouse
  • Lipopolysaccharides
  • Neuroprotective Agents
  • Anti-Inflammatory Agents
  • DNA-Binding Proteins